BioSpace News Archive

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application allowing Daré to conduct a single arm, open-label pivotal contraceptive efficacy study of Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive.

Morphic Therapeutic today announced the presentation of new phase 1 data from MORF-057 phase 1 studies at the United European Gastroenterology (UEG) Week 2022.

Leica Microsystems Inc., a technology leader in microscope and image analysis solutions, and S3 Medical have signed an exclusive distribution agreement.

Bluestar Genomics, Inc. today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP).

Ochre Bio, an innovator in chronic liver disease drug development, today announced the successful close of $30M in Series A financing.

Rocket Pharmaceuticals, Inc. today announced that Raj Prabhakar, M.B.A., Chief Business Officer, will deliver an in-person company presentation at the 2022 Cell & Gene Meeting on the Mesa on Tuesday, October 11, at 2:30 p.m. PT in Carlsbad, CA.

STALICLA SA today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).

Enable Biosciences, a leading diabetes and COVID diagnostics firm and CLIA- and CAP- certified laboratory, announced that Carolyn Bertozzi , PhD, co-founder of Enable Biosciences, was awarded the 2022 Nobel Prize in Chemistry for “the development of click chemistry and bioorthogonal chemistry.”

Lineage Cell Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a patent for the Company’s U.S. patent application No. 16/750,975, entitled “Dorsally-Derived Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells.”

Immune-Onc Therapeutics, Inc. today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China.